Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 2
1959 1
1961 2
1962 3
1963 4
1964 1
1965 11
1966 14
1967 13
1968 13
1969 8
1970 12
1971 20
1972 19
1973 17
1974 26
1975 22
1976 22
1977 29
1978 29
1979 35
1980 23
1981 24
1982 29
1983 44
1984 51
1985 54
1986 52
1987 52
1988 64
1989 52
1990 58
1991 47
1992 69
1993 53
1994 54
1995 73
1996 67
1997 78
1998 97
1999 99
2000 88
2001 121
2002 115
2003 121
2004 115
2005 121
2006 112
2007 110
2008 111
2009 115
2010 112
2011 138
2012 172
2013 168
2014 155
2015 135
2016 147
2017 150
2018 151
2019 150
2020 184
2021 181
2022 163
2023 148
2024 45

Text availability

Article attribute

Article type

Publication date

Search Results

4,389 results

Results by year

Filters applied: . Clear all
Page 1
Structural basis for ion selectivity in potassium-selective channelrhodopsins.
Tajima S, Kim YS, Fukuda M, Jo Y, Wang PY, Paggi JM, Inoue M, Byrne EFX, Kishi KE, Nakamura S, Ramakrishnan C, Takaramoto S, Nagata T, Konno M, Sugiura M, Katayama K, Matsui TE, Yamashita K, Kim S, Ikeda H, Kim J, Kandori H, Dror RO, Inoue K, Deisseroth K, Kato HE. Tajima S, et al. Among authors: ikeda h. Cell. 2023 Sep 28;186(20):4325-4344.e26. doi: 10.1016/j.cell.2023.08.009. Epub 2023 Aug 30. Cell. 2023. PMID: 37652010 Free PMC article.
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D. Sato Y, et al. Among authors: ikeda h. Chest. 2022 Nov;162(5):1188-1198. doi: 10.1016/j.chest.2022.05.035. Epub 2022 Jun 1. Chest. 2022. PMID: 35661746
Response to RMED-D-22-00,258.R1.
Ohno Y, Aoyagi K, Arakita K, Doi Y, Kondo M, Banno S, Kasahara K, Ogawa T, Kato H, Hase R, Kashizaki F, Nishi K, Kamio T, Mitamura K, Ikeda N, Nakagawa A, Fujisawa Y, Taniguchi A, Ikeda H, Hattori H, Murayama K, Toyama H. Ohno Y, et al. Among authors: ikeda h. Jpn J Radiol. 2022 Aug;40(8):860-861. doi: 10.1007/s11604-022-01308-8. Epub 2022 Jun 25. Jpn J Radiol. 2022. PMID: 35751793 Free PMC article. No abstract available.
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
Ishihara M, Kitano S, Kageyama S, Miyahara Y, Yamamoto N, Kato H, Mishima H, Hattori H, Funakoshi T, Kojima T, Sasada T, Sato E, Okamoto S, Tomura D, Nukaya I, Chono H, Mineno J, Kairi MF, Diem Hoang Nguyen P, Simoni Y, Nardin A, Newell E, Fehlings M, Ikeda H, Watanabe T, Shiku H. Ishihara M, et al. Among authors: ikeda h. J Immunother Cancer. 2022 Jun;10(6):e003811. doi: 10.1136/jitc-2021-003811. J Immunother Cancer. 2022. PMID: 35768164 Free PMC article. Clinical Trial.
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, Sato Y, Uenami T, Saito G, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: ikeda h. Eur J Cancer. 2021 Dec;159:144-153. doi: 10.1016/j.ejca.2021.09.041. Epub 2021 Nov 5. Eur J Cancer. 2021. PMID: 34749119
Aging, cancer, and antitumor immunity.
Ikeda H, Togashi Y. Ikeda H, et al. Int J Clin Oncol. 2022 Feb;27(2):316-322. doi: 10.1007/s10147-021-01913-z. Epub 2021 Mar 30. Int J Clin Oncol. 2022. PMID: 33783658 Review.
State-of-the-art MR Imaging for Thoracic Diseases.
Tanaka Y, Ohno Y, Hanamatsu S, Obama Y, Ueda T, Ikeda H, Iwase A, Fukuba T, Hattori H, Murayama K, Yoshikawa T, Takenaka D, Koyama H, Toyama H. Tanaka Y, et al. Among authors: ikeda h. Magn Reson Med Sci. 2022 Mar 1;21(1):212-234. doi: 10.2463/mrms.rev.2020-0184. Epub 2021 Apr 29. Magn Reson Med Sci. 2022. PMID: 33952785 Free PMC article. Review.
Diagnostic approach for mediastinal masses with radiopathological correlation.
Taka M, Kobayashi S, Mizutomi K, Inoue D, Takamatsu S, Gabata T, Matsumoto I, Ikeda H, Kobayashi T, Minato H, Abo H. Taka M, et al. Among authors: ikeda h. Eur J Radiol. 2023 May;162:110767. doi: 10.1016/j.ejrad.2023.110767. Epub 2023 Mar 11. Eur J Radiol. 2023. PMID: 36921376 Review.
Overview of MRI for pulmonary functional imaging.
Ohno Y, Hanamatsu S, Obama Y, Ueda T, Ikeda H, Hattori H, Murayama K, Toyama H. Ohno Y, et al. Among authors: ikeda h. Br J Radiol. 2022 Apr 1;95(1132):20201053. doi: 10.1259/bjr.20201053. Epub 2021 Feb 2. Br J Radiol. 2022. PMID: 33529053 Free PMC article. Review.
Artificial placenta technology: History, potential and perception.
Usuda H, Watanabe S, T H, Saito M, Sato S, Ikeda H, Kumagai Y, Choolani MC, Kemp MW. Usuda H, et al. Among authors: ikeda h. Placenta. 2023 Sep 26;141:10-17. doi: 10.1016/j.placenta.2022.10.003. Epub 2022 Oct 13. Placenta. 2023. PMID: 37743742 Review.
4,389 results